louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01919125: Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)
Official title: A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hepatitis C, Chronic
Keywords: Chronic hepatitis C
Hepatitis C virus
HCV
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2013-08-08
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the pharmacokinetics (PK) and safety and tolerability of single-dose administration of IDX719 in participants with normal hepatic function and participants with varying degrees of hepatic impairment.


Eligibility criteria: Inclusion Criteria:

* Read and sign the written informed consent form (ICF) after the nature of the study has been fully explained.
* All subjects of childbearing potential must have agreed to use a double method of birth control (one of which must be a barrier) from Screening through at least 90 days after the last dose of the study drug.
* Male subjects have agreed not to donate sperm from Day -1 through 90 days after the last dose of study drug.

Exclusion Criteria:

* Pregnant or breastfeeding.
* Other clinically significant medical conditions or laboratory abnormalities

Primary outcomes:
measure: Maximum plasma concentration (Cmax)
timeFrame: Up to 6 days
measure: Time to maximum plasma concentration (Tmax)
timeFrame: Up to 6 days
measure: Area under the curve (AUC) from time zero to last measurable concentration (AUC0-last)
timeFrame: Up to 6 days
measure: AUC from time zero to infinity (AUC0-~)
timeFrame: Up to 6 days
measure: AUC from time zero to 24 hours (AUC0-24h)
timeFrame: Up to 6 days
measure: Plasma concentration 24 hours after dosing (C24h)
timeFrame: Up to 6 days
measure: Apparent terminal elimination rate constant
timeFrame: Up to 6 days
measure: Observed terminal half-life (T1/2)
timeFrame: Up to 6 days
Secondary outcomes:
measure: Percentage of participants experiencing serious adverse events (SAEs)
timeFrame: Up to 6 days
measure: Percentage of participants experiencing an adverse event (AE)
timeFrame: Up to 6 days
measure: Percentage of participants experiencing Grade 1-4 laboratory abnormalities
timeFrame: Up to 6 days
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01192425: Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Official title: P06-001: (EX)Amination of (P)NH, by (L)Evel (O)f CD59 on (RE)d and White Blood Cells, in Bone Marrow Failure Syndromes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemoglobinuria
Keywords: PNH clone cells
Aplastic Anemia
AA
Myelodysplastic Syndromes
MDS
bone marrow failure syndromes
FLAER
Paroxysmal Nocturnal Hemoglobinuria
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2010-09-01
Enrollment: 5580
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients at least 10 years of age with aplastic anemia, myelodyplastic syndromes or other bone marrow failure syndromes.

Brief summary: Examine red and white blood cells of PNH patients with bone marrow failure syndromes.


Eligibility criteria: Inclusion Criteria:

* At least 10 years of age.
* Has aplastic anemia, myelodysplastic syndromes or other bone marrow failure syndromes

Exclusion Criteria:

* Has any condition that might interfere with the patient's participation

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04200625: Semaglutide vs Dulaglutide on Epicardial Adipose Tissue
Official title: Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Epicardial Fat
Lead sponsor: University of Miami
Sponsor class: OTHER
First posted: 2019-12-16
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Type 2 diabetic subjects who routinely come to the University of Miami Division of Diabetes, Endocrinology and Metabolism outpatient diabetic clinic, as standard of care.

Brief summary: Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Detailed description: This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records.

Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care.

Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes,
* BMI ≥27 kg/m2,
* Age ≥ 18 years old

Exclusion Criteria:

* Type 1 diabetes
* Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors or other GLP-1 agonist receptors
* History of diabetic ketoacidosis
* Known contraindications to GLP-1 receptor agonists such as previous history of pancreatitis or medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2
* Acute infective diseases, cancer or chemotherapy
* Use of systemic corticosteroids within the 3 months prior this study
* Known or suspected allergy to semaglutide or dulaglutide excipients or related products
* Pregnancy, breastfeeding or the intention of becoming pregnant

Primary outcomes:
measure: Epicardial Fat thickness
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Gianluca Iacobellis, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00434525: Laparoscopic Sleeve Gastrectomy With and Without Omentectomy
Official title: Metabolic Effects of Laparoscopic Sleeve Gastrectomy With or Without Omentectomy: Prospective Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Morbid Obesity
Keywords: Morbid obesity
Bariatric Surgery
Obesity Surgery
Omentectomy
Sleeve gastrectomy
Lead sponsor: North Texas Veterans Healthcare System
Sponsor class: FED
First posted: 2007-02-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * The investigators aim to determine the clinical and metabolic effects of sleeve gastrectomy with or without omentectomy in the treatment of morbid obesity.
* The investigators hypothesize that the endocrine suppression of ghrelin (appetite hormone)and resistin (insulin antagonist) provided by sleeve gastrectomy and omentectomy (omentum or intra-abdominal fat removal) will provide clinical and metabolic benefits for morbidly obese patients.

Detailed description: This is a phase 3 prospective randomized trial.

Eligibility criteria: Inclusion Criteria:

* Morbidly obese VETERANS ONLY (BMI\>35 with comorbidities or BMI\>40)
* Age \> 18

Exclusion Criteria:

* Pregnancy
* Uncontrolled medical or psychiatric conditions
* Previous bariatric procedure

Primary outcomes:
measure: Weight loss
timeFrame: 5 years
Secondary outcomes:
measure: Metabolic outcomes
timeFrame: 5 years
measure: Diabetes resolution
timeFrame: 5 years
Other outcomes:
Locations:
city: Dallas
country: United States
facility: VA North Texas
state: Texas
Study officials:
affiliation: VA North Texas
name: Esteban Varela, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00295425: CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.
Official title: Open, Multicenter, Randomized Clinical Trial in Patients With Moderate-Severe Psoriasis (PASI > 10) to Compare the Efficacy of Mycophenolate Mofetil Versus Cyclosporine A.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Psoriasis
Keywords: psoriasis
randomized clinical trial
cyclosporine A
mycophenolate mofetil
immunosuppression
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2006-02-23
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Psoriasis is an immuno-mediated skin disorder, which affects about 2-3% of the population worldwide. For moderate-severe forms of psoriasis systemic immunosuppression is the treatment of choice. This clinical trial was initiated to compare the safety and effectiveness of mycophenolate mofetil and cyclosporine A for the treatment of psoriasis. Patients are randomized to receive either 2.5 mg/kg BW cyclosporine A or 1 g bid mycophenolate mofetil. If after six weeks no decrease in the PASI score occures cyclosporine A doses are increased to 5 mg/kg BW for additional six weeks. In the other arm mycophenolate mofetil is increased to 1 g tid for additional six weeks.

Detailed description: Not needed.

Eligibility criteria: Inclusion Criteria:

* moderate-to-severe psoriasis (PASI Score equal and greated 10)
* written informed consent
* for female patients effective birth control

Exclusion Criteria:

* psoriasis arthritis
* psoriasis palmo-plantaris
* erythrodermic psoriasis
* drug-induced psoriasis
* pregnancy
* previous treatment with cyclosporine A or mycophenolate mofetil
* pregnancy
* reduced liver function
* high blood pressure
* reduced kidney function
* severe viral or bacterial infection
* 2 weeks before or after vaccinations
* innate or acquired immunodeficiency
* severe neurologic or psychiatric symptoms
* participation in other trials
* other reasons voiced by the treating physician

Primary outcomes:
measure: Comparison of the two treatment arms with regard to time until psoriasis recurrence.
Secondary outcomes:
measure: The treatment that leads to a 75% decrease of the initial PASI score.
measure: The time until complete remission.
measure: The time until partial remission has occured.
measure: The rate of complete remission.
measure: The rate of partial remission.
measure: The cumulative cyclosporine A or mycophenolate mofetil doses.
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: Nicolas Hunzelmann
city: Leipzig
country: Germany
facility: Prof. Michael Sticherling
Study officials:
affiliation: Department of Dermatology, University Hospital Muenster, Muenster, Germany
name: Stefan Beissert, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01824225: Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
Official title: Study of PRN and Every 2months Intravitreal Aflibercept After 3 Initial Monthly Injection for Age Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Age-related Macular Degeneration
Keywords: aflibercept
intravitreal injection
Lead sponsor: Nihon University
Sponsor class: OTHER
First posted: 2013-04-04
Enrollment: 100
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of age-related macular degeneration

Exclusion Criteria:

* Any treatment before intravitreal Aflibercept for age-related macular degeneration.
* Visual acuity above 0.1 in decimal visual acuity

Primary outcomes:
measure: Visual acuity after treatment by PRN or 2 months intravitreal Aflibercept
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Chiyoda-ku
country: Japan
facility: Surugadai Nihon university hospital
state: Tokyo
Study officials:
affiliation: Surugadai Nihon University Hospital
name: Mitsuko Yuzawa, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04350125: PRP for the Treatment of Erectile Dysfunction (ED)
Official title: A Pilot Study Evaluating the Use of Autologous Platelet-rich Plasma (PRP) for the Treatment of Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Erectile Dysfunction
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2020-04-16
Enrollment: 4
Sex: MALE
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Subjects treated in this study will be divided into 3 cohorts of 5. After the first cohort of 5 subjects have been treated and evaluated for safety, the second cohort of 5 subjects will proceed with treatment followed by review of events for safety. If determined safe to proceed the third cohort of 5 subjects will proceed with treatment.
Primary purpose: TREATMENT

Brief summary: Researchers are trying to determine the safety and efficacy of Platelet Rich Plasma (PRP) in the treatment of Erectile Dysfunction (ED).


Eligibility criteria: Inclusion Criteria:

* The patient must have given his informed and signed written consent
* The patient has ED for longer than 1 year but less than 5 years.
* The subject has a stable partner for at least 3 months.
* The patient is PDE5i responsive, meaning he is able to achieve and maintain an erection under the effect of the maximal dosage of PDE5i
* IIEF-EF, EHS, SEP 2+3, and GAQ Domain score of 17-20 Mild to moderate vascular erectile dysfunction: PSV \> 25 cm/sec

Exclusion Criteria:

The patient is participating in another study that may interfere with the results or conclusions of this study

* History of radical prostatectomy or pelvic cancer surgery
* Prior history of pelvic malignancies
* Prior pelvic radiation therapy
* Neurological disease which effects erectile function (Spinal cord injury, iatrogenic injury to the pelvic or cavernous nerves)
* Psychiatric disease which effects erectile function
* The patient is taking blood thinners
* History of Diabetes Mellitus
* History of Coronary Artery Disease
* Evidence Based Criteria: Doppler Clinical Exam ( PSV \< 25 cm/sec defined criteria for severe erectile dysfunction not likely to respond to approved medical therapies)
* Biochemical evidence of Hypogonadism (total Testosterone \< 300 ng/dL)

Primary outcomes:
measure: Treatment-related adverse events
timeFrame: 35 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jacksonville
country: United States
facility: Mayo Clinic in Florida
state: Florida
Study officials:
affiliation: Mayo Clinic
name: Gregory Broderick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04761848: Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
Official title: Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease: A Randomized, Controlled Trial.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Fatty Liver, Nonalcoholic
Lead sponsor: Sadat City University
Sponsor class: OTHER
First posted: 2021-02-21
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the current study is to evaluate the safety and efficay of cilostazol in treatment of patients with fatty liver disease. Several previous reports have shown that cilostazol ameliorates lipid imbalances in NAFLD. Cilostazol appeared to exert beneficial effects against NAFLD


Eligibility criteria: Inclusion Criteria:

* Adults between 18 and 60 years of age, both men and women,
* Clinical diagnosis of NAFLD, confirmed by imaging exams,
* Patients who present levels above the reference values of ALT, AST and ferritin.

Exclusion Criteria:

* Women in the menacing period, with the exception of those who have performed definitive sterilization, such as hysterectomy or tubal ligation.
* Patients with established prior diagnosis of chronic noncommunicable disease (congestive heart failure, decompensated or severe lung disease, neoplasms, renal disease, advanced liver disease - Child Pugh C classification)
* Patients with schistosomiasis;
* Hemochromatosis
* Wilson's disease
* Viral or autoimmune hepatitis
* HIV virus carriers
* Woman who is breastfeeding
* Users of illicit drugs
* Patients with an intake of more than 20 g / day of alcohol and / or past alcoholism with abstention less than 6 months;
* Patients with ingestion of medications such as steroids, estrogens, amiodarone, warfarin, anti-convulsants, antipsychotics, tamoxifen or other chemotherapeutic agents in the last 6 months
* Patients with clinically manifest infections or inflammation, surgery, trauma or hospitalization in the last 30 days
* Chronic non-hepatic degenerative diseases (sclerosis, Parkinson's disease or -Alzheimer's disease)
* Patients who do not participate in all stages of the research.

Primary outcomes:
measure: Hepatic transaminases
timeFrame: week 12
measure: Serum ferritin
timeFrame: week 12
Secondary outcomes:
measure: Lipid profile
timeFrame: week 12
measure: Glycated haemoglobin
timeFrame: week 12
measure: Serum stem cell transforming factor beta
timeFrame: 12 weeks
measure: Adverse effects
timeFrame: 12 weeks
measure: FAM19A5 serum level
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Faculty of Pharmacy
state: Menoufia
Study officials:
References:
Clinical trial NCT00661648: Effect of an Artificial Pancreas in Patients Undergoing Pancreatic Resection
Official title: Prevention for Surgical Site Infection After Pancreatic Resection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pancreatic Diseases
Keywords: surgery
Lead sponsor: Kochi University
Sponsor class: OTHER
First posted: 2008-04-18
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study evaluated that strict control of perioperative blood glucose following pancreatic resection by using an artificial pancreas would improve postoperative surgical site infection.

Detailed description: This study recruited 50 patients undergoing elective pancreatic resection for pancreatic diseases. Perioperative blood glucose concentration was continuously monitored using an artificial pancreas system. We prospectively divided into two groups: one for whom glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale and another that received programmed infusion of insulin determined by the control algorithm of the artificial pancreas.

Eligibility criteria: Inclusion Criteria:

* patients undergoing elective pancreatic resection for pancreatic diseases.

Exclusion Criteria:

* weight loss greater than 10% during the previous 6 months
* sign of distant metastasis
* respiratory, renal, or heart disease

Primary outcomes:
measure: the incidence of surgical site infection
timeFrame: 30th postoperative day
Secondary outcomes:
measure: the incidence of hypoglycemia and cost during the hospitalization
timeFrame: during the hospitalization
Other outcomes:
Locations:
city: Nankoku-City
country: Japan
facility: Kochi Medical School
state: Kochi
Study officials:
affiliation: Kochi Medical School
name: Takehiro Okabayashi, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04369248: Hepassocin Levels in Patients With Polycystic Ovary Syndrome
Official title: Hepassocin Levels in Patients With Polycystic Ovary Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepassocin (Hepatocyte-derived Fibrinogen-related Protein 1)
Polycystic Ovary Syndrome
Obesity
Insulin Resistance
Lead sponsor: Gaziosmanpasa Research and Education Hospital
Sponsor class: OTHER_GOV
First posted: 2020-04-30
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 60 patients with PCOS aged between 18 and 35 and age matched 30 healthy women with BMI \< 30 were enrolled to the study.

Brief summary: The investigators aimed to investigate hepassocin levels in patients with polycystic ovary syndrome (PCOS). There are 3 groups aged between 18 and 35 years as non-obese healthy women, non-obese women with PCOS, and obese women (BMI\>30) with PCOS.

Detailed description: Hepassocin, also known as Fibrinogen-like-protein or hepatocyte-derived fibrinogen-related protein 1, is a new marker for obesity and insulin resistance. In hepatic injury, it protects liver cells and promotes regeneration. High levels of hepassocin was shown to be independently associated with HOMA-IR and diabetes. Since insulin resistance is known to be seen in patients with PCOS, it may be expected that hepassocin levels may be higher in this group of patients.

Eligibility criteria: Inclusion Criteria:

* 60 patients with PCOS aged between 18 and 35 and age-matched 30 healthy women with BMI\<30

Exclusion Criteria:

Premature ovarian failure (FSH \>30 mIU/mL), tumors secreting androgens, non-classical congenital adrenal hyperplasia, Cushing syndrome and irregular menses due to thyroid dysfunction (TSH \>5 mIU/L ), hyperprolactinemia, more than twofold high transaminase levels (\>70 U/L), patients with cigarette smoking, alcohol consumption, oral contraceptives use, medications that are affecting liver function test, insulin metabolism and lipid metabolism, patients with a history of chronic diseases such as diabetes mellitus, hypertension, chronic liver disease, chronic kidney disease, autoimmune disease, inflammatory disease, malignant disease, bleeding disorders, and thrombosis were also excluded. All the patients were beta-HCG, hepatitis B surface antigen, and hepatitis C antibody negative.

-

Primary outcomes:
measure: Hepassocin levels in patients with polycystic ovary syndrome
timeFrame: January 2020-March 2020
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Gaziosmanpasa Taksim Education and Research Hospital
Study officials:
affiliation: Gaziosmanpasa Taksim Education and Research Hospital
name: fatma ketenci gencer
role: STUDY_DIRECTOR
affiliation: Gaziosmanpasa Taksim Education and Research Hospital
name: sibel bektas
role: STUDY_CHAIR
References: